Pharma Mar SA
Maria Pascual currently serves as VP & Chief Regulatory Officer at PharmaMar since February 2024. Previously, Maria held the position of Chief Regulatory Officer at Minoryx Therapeutics from March 2019 to January 2024, and served as a Board Member at European Biopharmaceutical Enterprises (EBE) from June 2018 to June 2020. Maria's extensive experience at TiGenix spanned from 2004 to 2019 in various regulatory roles, culminating in the position of VP Regulatory Affairs & Corporate Quality. Additionally, Maria has held leadership roles with EFPIA, including Chairman of several committees focused on advanced therapies. Maria's earlier career includes roles in clinical development and research at institutions such as Genetrix, National Research Council (CSIC), Mayo Clinic, and Leiden University Medical Center. Maria is an alumna of the Universitat de Barcelona and Universidad de Granada, with a degree in Pharmacy, and has pursued advanced studies in Immunology.
This person is not in the org chart
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.